Ratings Astellas Pharma Inc. Deutsche Boerse AG

Equities

YPH

JP3942400007

Market Closed - Deutsche Boerse AG Other stock markets 03:11:14 2024-05-31 am EDT			5-day change	1st Jan Change
8.808 ^EUR	+0.69%		-1.50%	-19.78%

May. 31	U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date	CI
May. 21	Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

This company will be of major interest to investors in search of a high dividend stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

With an expected P/E ratio at 145.29 and 33.94 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ASTELLAS PHARMA INC.	-19.78%	17.66B	-
ELI LILLY AND COMPANY	+40.73%	739B	C+
NOVO NORDISK A/S	+32.83%	598B	B
JOHNSON & JOHNSON	-6.42%	353B	C+
MERCK & CO., INC.	+15.15%	318B	B-
ABBVIE INC.	+4.05%	285B	C+
ASTRAZENECA PLC	+15.00%	240B	B+
ROCHE HOLDING AG	-5.52%	206B	A+
AMGEN INC.	+6.19%	164B	C+
PFIZER, INC.	-0.45%	162B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes